Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc. | Niktimvo (axatilimab-csfr) - (MAXPIRe) | Idiopathic pulmonary fibrosis (IPF) | Phase 2 | Ongoing | Intravenous | Respiratory |
| Syndax Pharmaceuticals Inc. | Revumenib with venetoclax and decitabine/cedazuridine - (SAVE) | R/R or newly diagnosed AML | Phase 2 | Data Released | Oral | Oncology |
| Syndax Pharmaceuticals Inc. | Entinostat plus TECENTRIQ (atezolizumab) - (ENCORE 602) | Triple negative breast cancer (TNBC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Synlogic Inc. | labafenogene marselecobac (SYNB1934) - (Synpheny-3) | Phenylketonuria (PKU) | Phase 3 | Trial Discontinued | oral | Genetic Disorder |
| Synlogic Inc. | labafenogene marselecobac (SYNB1934) - (Synpheny-3) | Phenylketonuria (PKU) | Phase 3 | Trial Discontinued | oral | Genetic Disorder |
| Synlogic Inc. | labafenogene marselecobac (SYNB1934) - (Synpheny-3) | Phenylketonuria (PKU) | Phase 3 | Trial Discontinued | oral | Genetic Disorder |
| Synlogic Inc. | labafenogene marselecobac (SYNB1934) - (Synpheny-3) | Phenylketonuria (PKU) | Phase 3 | Trial Discontinued | oral | Genetic Disorder |
| Synlogic Inc. | SYNB1618 - (SynPheny-1) | Phenylketonuria (PKU) | Phase 2 | Trial Planned | oral | Genetic Disorder |
